Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)

NCT01283074 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01283074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01283074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
May 31, 2009
Completion date
November 30, 2012
Enrollment
107 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, chronic